Carbohydrate Interactions and HIV-1

  • Thomas Kieber-Emmons
Part of the Infectious Agents and Pathogenesis book series (IAPA)


Human Immunodeficiency Virus Human Immunodeficiency Virus Infection Acquire Immune Deficiency Syndrome Simian Immunodeficiency Virus Human Immunodeficiency Virus Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mbemba, E., Carre, V., Atemezem, A., Saffar, L., Gluchan, J. C., and Gattegno, L., 1996, Inhibition of human immunodeficiency virus infection of CD4+ cells by CD4-free glyco-peptides from monocytic U937 cells, AIDS Res. Hum. Retrovir. 12:47–53.PubMedGoogle Scholar
  2. 2.
    Bhat, S., Mettus, R. V., Reddy, E. P., Ugen, K. E., Srikanthan, V., Williams, W. V., and Weiner D. B., 1993, The galactosyl ceramide/sulfatide receptor binding region of HIV-1 gp120 maps to amino acids 206275, AIDS Res. Hum. Retrovir. 9:175–181.PubMedGoogle Scholar
  3. 3.
    Pearce, P. R., and Phillips, D. M., 1996, Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1, Biol. Reprod. 54:173–182.Google Scholar
  4. 4.
    Leydet, A., Jeantet, S. C., Bouchitte, C., Moullet, C., Boyer, B., Roque, J. P., Witvrouw, M., Este, J., Snoeck, R., Andrei, G., and De, C. E., 1997, Polyanion inhibitors of human immunodeficiency virus and other viruses. 6. Mecille-like anti-HIV polyanionic compounds based on a carbohydrate core, J. Med. Chem. 40:350–356.PubMedGoogle Scholar
  5. 5.
    Bernstein, H. B., Tucker, S. P., Hunter, E., Schutzbach, J. S., and Compans, R. W., 1994, Human immunodeficiency virus type 1 envelope glycoprotein is modified by 0-linked oligosaccharides, J. Virol. 68:463–468.PubMedGoogle Scholar
  6. 6.
    Gram, G. J., Hemming, A., Bolmstedt, A., Jansson, B., Olofsson, S., Akerblom, L., Nielsen, J. O., and Hansen, J. E., 1994, Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4, Arch. Virol. 139:253–261.CrossRefPubMedGoogle Scholar
  7. 7.
    Liedtke, S., Adamski, M., Geyer, R., Pfutzner, A., Rubsamen, W. H., and Geyer, H., 1994, Oligosaccharide profiles of HIV-2 external envelope glycoprotein: Dependence on host cells and virus isolates, Glycobiology 4:477–484.PubMedGoogle Scholar
  8. 8.
    Trkola, A., Purtscher, M., Muster, T., Ballaun, C., Buchacher, A., Sullivan, N., Srinivasan, K., Sodroski, J., Moore, J. P., and Katinger, H., 1996, Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immuno-deficiency virus type 1, J. Virol. 70:1100–1108.PubMedGoogle Scholar
  9. 9.
    Moore, J. P., Cao, Y., Qing, L., Sattentau, Q. J., F’yati, J., Koduri, R., Robinson, J., Barbas, C., Burton, D. R., and Ho, D. D., 1995, Primary isolates of human immunodeficiencyvirus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120, J. Virol. 69:101–109.PubMedGoogle Scholar
  10. 10.
    Hansen, J. E., Jansson, B., Gram, G. J., Clausen, H., Nielsen, J. O., and Olofsson, S., 1996, Sensitivity of HIV-1 to neutralization by antibodies against 0-linked carbohydrate epitopes despite deletion of O-glycosylation signals in the V3 loop, Arch. Virol. 141:291–300.CrossRefPubMedGoogle Scholar
  11. 11.
    Clark, G. F., Dell, A., Morns, H. R., Patankar, M., Oehninger, S., and Seppala, M., 1997, Viewing AIDS from a glycobiological perspective: Potential linkages to the human feto-embryonic defence system hypotheses, Mol. Hum. Reprod. 3:5–13.PubMedGoogle Scholar
  12. 12.
    Nara, P., 1996, Humoral immunity to HIV-1: Lethal force or trojan horse, in: Immunology of HIV Infection (S. Gupta, ed.), Plenum Press, New York, pp. 243–276.Google Scholar
  13. 13.
    Fenouillet, E., Gluckman, J. C., and Jones, I. M., 1994, Functions of HIV envelope glycans, Trends Biochem. Sci. 19:65–70.CrossRefPubMedGoogle Scholar
  14. 14.
    Zanetta, J. P., Badache, A., Maschke, S., Marschal, P., and Kuchler, S., 1994, Carbohydrates and soluble lectins in the regulation of cell adhesion and proliferation, Histol. Histopathol. Google Scholar
  15. 15.
    Preston, A., Mandrell, R. E., Gibson, B. W., and Apicella, M. A., 1996, The lipooligosac-charides of pathogenic Gram-negative bacteria, Crit. Rev. Microbiol. 22:139–180.PubMedGoogle Scholar
  16. 16.
    Moran, A. P., Prendergast, M. M., and Appelmelk, B. J., 1996, Molecular mimicry of host structures by bacterial lipopolysaccharides and its contribution to disease, FEMS Immunol. Med. Microbiol. 16:105–115.PubMedGoogle Scholar
  17. 17.
    Appelmelk, B. J., Simoons, S. I., Negrini, R., Moran, A. P., Aspinall, G. O., Forte, J. G., De, V. T., Quan, H., Verboom, T., Maaskant, J. J., Ghiara, P., Kuipers, E. J., Bloemena, E., Tadema, T. M., Townsend, R. R., et al., 1996, Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity, Infection Immunity 64:2031–2040.PubMedGoogle Scholar
  18. 18.
    Muller, W. E., Bachmann, M., Weiler, B. E., Schroder, H. C., Uhlenbruck, G., Shinoda, T., Shimizu, H., and Ushjima, H., 1991, Antibodies against defined carbohydrate structures of Candida albicans protect H9 cells against infection with human immunodeficiency virus-1 in vitro, J. Acquired Immune Defic. Syndr. 4:694–703.Google Scholar
  19. 19.
    McAlarney, T., Ogino, M., Apostolski, S., and Latov, N., 1995, Specificityand cross-reactivity of anti-galactocerebroside antibodies, Immunol. Inv. 24:595–606.Google Scholar
  20. 20.
    Hansen, J. E., Clausen, H., Hu, S. L., Nielsen, J. O., and Olofsson, S., 1992, An 0-linked carbohydrate neutralization epitope of HIV-1 gp120 is expressed by HIV-1 env gene recombinant vaccinia virus, Arch. Virol. 126:11–20.CrossRefPubMedGoogle Scholar
  21. 21.
    Hansen, J. E., Nielsen, C., Arendrup, M., Olofsson, S., Mathiesen, L., Nielsen, J. O., and Clausen, H., 1991, Broadly neutralizing antibodies targeted to mucin-type carbohydrate epitopes of human immunodeficiency virus, J. Virol. 65:6461–6467.PubMedGoogle Scholar
  22. 22.
    Back, N. K., Smit, L., De, J. J., Keulen, W., Schutten, M., Goudsmit, J., and Tersmette, M., 1994, An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization, Virology 199:431–438.CrossRefPubMedGoogle Scholar
  23. 23.
    Arendrup, M., Hansen, J. E., Clausen, H., Nielsen, C., Mathiesen, L. R., and Nielsen, J. O., 1991, Antibody to histo-blood group A antigen neutralizes HIV produced by lymphocytes from blood group A donors but not from blood group B or 0 donors, AIDS 5:441–444.PubMedGoogle Scholar
  24. 24.
    Dabelsteen, E., 1996, Cell surface carbohydrates as prognostic markers in human carcinomas, J. Pathol. 179:358–369.CrossRefPubMedGoogle Scholar
  25. 25.
    Lefebvre, J. C., Giordanengo, V., Doglio, A., Cagnon, L., Breittmayer, J. P., Peyron, J. F., and Lesimple, J., 1994, Altered sialylation of CD45 in HIV-1-infected T lymphocytes, Virology 199:265–274.CrossRefPubMedGoogle Scholar
  26. 26.
    Lefebvre, J. C., Giordanengo, V., Limouse, M., Doglio, A., Cucchiarini, M., Monpoux, F., Mariani, R., and Peyron, J. F., 1994, Altered glycosylation of leukosialin, CD43, in HIV-1-infected cells of the CEM line, J. Exp. Med. 180:1609–1617.CrossRefPubMedGoogle Scholar
  27. 27.
    Adachi, M., Hayami, M., Kashiwagi, N., Mizuta, T., Ohta, Y., Gill, M. J., Matheson, D. S., Tamaoki, T., Shiozawa, C., and Hakomori, S., 1988, Expression of LeY antigen in human immunodeficiency virus-infected human T cell lines and in peripheral lymphocytes of patients with acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC), J. Exp. Med. 167:323–331.CrossRefPubMedGoogle Scholar
  28. 28.
    Gattegno, L., Ramdani, A., Joualt, T., Saffar, L., and Gluckman, J. C., 1992, Lectin-carbohydrate interactions and infectivity of human immunodeficiency virus type 1 (HIV-1), AIDS Res. Hum. Retrovir. 8:27–37.PubMedGoogle Scholar
  29. 29.
    Kashiwagi, N., Gill, M. J., Adachi, M., Church, D., Wong, S. J., Poon, M. C., Hakomori, S., Tamaoki, T., and Shiozawa, C., 1994, Lymphocyte membrane modifications induced by HlV infection, Tohoku J. Exp. Med. 173:115–131.PubMedCrossRefGoogle Scholar
  30. 30.
    Hamadeh, R M., Galili, U., Zhou, P., and Griffiss, J. M., 1995, Anti-alphagalactosyl immunoglobulin A (IgA), IgG, and IgM in human secretions, Clin. Diag. Lab. Immunol. 2:125–131.Google Scholar
  31. 31.
    Teneberg, S., Lonnroth, I., Torres, L. J., Galili, U., Halvarsson, M. O., Angstrom, J., and Karlsson, K. A., 1996, Molecular mimicry in the recognition of glycosphingolipids by Gal alpha 3 Gal beta 4 GlcNAc beta-binding Clostridium difficile toxin A, human natural anti alpha-galactosyl IgG and the monoclonal antibody Gal-13: Characterization of a binding-active human glycosphingolipid, non-identical with the animal receptor, Glycobiology 6: 599–609.PubMedGoogle Scholar
  32. 32.
    Reed, D. J., Lin, X., Thomas, T. D., Birks, C. W., Tang, J., and Rother, R. P., 1997, Alteration of glycosylation renders HIV sensitive to inactivation by normal human serum, J. Immunol. 159:4356–4361.PubMedGoogle Scholar
  33. 33.
    Moore, J. P., Sattentau, Q. J., Wyatt, R., and Sodroski, J., 1994, Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies, J. Virol. 68:469–484.PubMedGoogle Scholar
  34. 34.
    Ditzel, H. J,, Parren, P. W., Binley, J. M., Sodroski, J., Moore, J. P., Barbas, C., and Burton, D. R., 1997, Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries, J. Mol. Biol. 267: 684–695.CrossRefPubMedGoogle Scholar
  35. 35.
    Sattentau, Q. J., and Moore, J. P., 1995, Human immunodeficiencyvirus type 1 neutralization is determined by epitope exposure on the gp120 oligomer, J. Exp. Med. 182:185–196.CrossRefPubMedGoogle Scholar
  36. 36.
    Zhang, Y. M., Dawson, S. C., Landsman, D., Lane, H. C., and Salzman, N. P., 1994, Persistence of four related human immunodeficiency virus subtypes during the course of zidovudine therapy: Relationship between virion RNA and proviral DNA, J. Virol. 68: 425–432.PubMedGoogle Scholar
  37. 37.
    Overbaugh, J., Anderson, R. J., Ndinya, A. J., and Kreiss, J. K, 1996, Distinct but related human immunodeficiency virus type 1 variant populations in genital secretions and blood, AIDS Res. Hum. Retrovir. 12:107–115.PubMedGoogle Scholar
  38. 38.
    Gao, F., Morrison, S. G., Robertson, D. L., Thornton, C. L., Craig, S., Karlsson, G., Sodroski, J., Morgado, M., Galvao, C. B., von Briesen, H., et al., 1996, Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization, J. Virol. 70:1651–1667.PubMedGoogle Scholar
  39. 39.
    Manca, F., 1992, Galactose receptors and presentation of HIV envelope glycoprotein to specific human T cells, J. Immunol. 148:2278–2282.PubMedGoogle Scholar
  40. 40.
    Benjouad, A., Mabrouk, K, Gluckman, J. C., and Fenouillet, E., 1994, Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type-1 envelope glycoprotein, FEBS Lett. 341:244–250.CrossRefPubMedGoogle Scholar
  41. 41.
    Schonning, K., Jansson, B., Olofsson, S., and Hansen, J. E., 1996, Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1, J. Gen. Virol. 77:753–758.PubMedGoogle Scholar
  42. 42.
    Huang, X., Barchi, J. J., Lung, F. D., Roller, P. P., Nara, P. L., Muschik, J., and Garrity, R. R., 1997, Glycosylation affects both the three-dimensional structure and antibody binding properties of the HIV-IIIIB Gp120 peptide RP135, Biochemistry 36:10846–10856.PubMedGoogle Scholar
  43. 43.
    Huang, X., Smith, M. C., Berzofsky, J. A., and Barchi, J. J., 1996, Structural comparison of a 15 residue peptide from the V3 loop of HIV-IIIIb and an O-glycosylated analogue, FEBS Lett. 393:280–286.CrossRefPubMedGoogle Scholar
  44. 44.
    Bolmstedt, A., Olofsson, S., Sjogren, J. E., Jeansson, S., Sjoblom, I., Akerblom, L., Hansen, J. E., and Hu, S. L., 1992, Carbohydrate determinant NeuAc-Gal beta (1–-4) of N-linked glycans modulates the antigenic activity of human immunodeficiencyvirus type 1 glycoprotein gp120, J. Gen. Virol. 73:3099–3105.PubMedGoogle Scholar
  45. 45.
    Chackerian, B., Rudensey, L. M., and Overbaugh, J., 1997, Specific N-linked and 0-linked glycosylation modifications in the envelope VI domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies, J. Virol. 71: 7719–7727.PubMedGoogle Scholar
  46. 46.
    Willey, R. L., Shibata, R., Freed, E. O., Cho, M. W., and Martin, M. A., 1996, Differential glycosylation, virion incorporation, and sensitivity to neutralizing antibodies of human immunodeficiency virus type 1 envelope produced from infected primary T-lymphocyte and macrophage cultures, J. Virol. 70:6431–6436.PubMedGoogle Scholar
  47. 47.
    Sorensen, A. M., Nielsen, C., Arendrup, M., Clausen, H., Nielsen, J. O., Osinaga, E., Roseto, A., and Hansen, J. E., 1994, Neutralization epitopes on HIV pseudotyped with HTLV-I: Conservation of carbohydrate epitopes, J. Acquired Immune Defic. Syndr.7:116–123; Erratum, J. Acquired Immune Defic. Syndr. 7:740.Google Scholar
  48. 48.
    Arendrup, M., Sonnerborg, A., Svennerholm, B., Akerblom, L., Nielsen, C., Clausen, H., Olofsson, S., Nielsen, J. O., and Hansen, J. E., 1993, Neutralizing antibody response during human immunodeficiency virus type 1 infection: Type and group specificity and viral escape, J. Gen. Virol. 74:855–863.PubMedGoogle Scholar
  49. 49.
    Yu, X. F., Wang, Z., Beyrer, C., Celentano, D. D., Khamboonruang, C., Allen, E., and Nelson, K., 1995, Phenotypic and genotypic characteristics of human immunodeficiency virus type 1 from patients with AIDS in northern Thailand, J. Virol. 69:4649–4655.PubMedGoogle Scholar
  50. 50.
    Kieber-Emmons, T., Jameson, B. A., and Morrow, W. J., 1989, The gp120-CD4 interface: Structural, immunological and pathological considerations, Biochim. Biophys. Acta 989: 281–300.PubMedGoogle Scholar
  51. 51.
    Garrity, R. R., Rimmelzwaan, G., Minassian, A., Tsai, W. P., Lin, G., de Jong, J. J., Goudsmit, J., and Nara, P. L., 1997, Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope, J. Immunol. 159:279–289.PubMedGoogle Scholar
  52. 52.
    Mond, J. J., Lees, A., and Snapper, C. M., 1995, T cell-independent antigens type 2, Annu. Rev. Immunol. 13:655–692.CrossRefPubMedGoogle Scholar
  53. 53.
    Agadjanyan, M., Luo, P., Westerink, M. A. J., Carey, L. A., Hutchins, W., Steplewski, Z., Weiner, D. B., and Kieber-Emmons, T., 1997, Peptide mimicry of carbohydrate epitopes on human immunodeficiency virus, Nature Biotechnol. 15:547–551.CrossRefGoogle Scholar
  54. 54.
    Hutchins, W., Adkins, A., Kieber-Emmons, T., and Westerink, M. A. J., 1996, Molecular characterization of a monoclonal antibody produced in response to a group-C meningococcal polysaccharide peptide mimic, Mol. Immunol. 33:503–510.CrossRefPubMedGoogle Scholar
  55. 55.
    Kieber-Emmons, T., Luo, P., Qiu, J., Agadjanyan, M., Carey, L., Hutchins, W., Westerink, M. A. J., and Steplewski, Z., 1997, Peptide mimicry of adenocarcinoma-associated carbohydrate antigens, Hybridoma 16:3–10.PubMedCrossRefGoogle Scholar
  56. 56.
    Westerink, M. A. J., Giardina, P. C., Apicella, M. A., and Kieber-Emmons, T., 1995, Peptide mimicry of the meningococcal group C capsular polysaccharide, Proc. Natl. Acad. Sci. USA 92:4021–4025.PubMedGoogle Scholar
  57. 57.
    Westerink, M. A. J., Campagnari, A. A., Giardina, P., and Apicella, M. A., 1994, Antiidiotype antibodies as surrogates for polysaccharide vaccines, Ann. N. Y. Acad. Sci. 730:209–216.PubMedGoogle Scholar
  58. 58.
    Scott, J. K., Loganathan, D., Easley, R. B., Gong, X., and Goldstein, I. J., 1992, A family of concanavalin A-binding peptides from a hexapeptide epitope library, Proc. Natl. Acad. Sci. USA 89:5398–5402.PubMedGoogle Scholar
  59. 59.
    Oldenburg, K. R., Loganathan, D., Goldstein, I. J., Schultz, P. G., and Gallop, M. A., 1992, Peptide ligands for a sugar-binding protein isolated from a random peptide library, Proc. Natl. Acad. Sci. USA 895393–5397.Google Scholar
  60. 60.
    Hoess, R., Brinkmann, U., Handel, T., and Pastan, I., 1993, Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3, Gene 12843–49.Google Scholar
  61. 61.
    Valadon, P., Nussbaum, G., Boyd, L. F., Margulies, D. H., and Scharff, M. D., 1996, Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans, J. Mol. Biol. 261:11–22.CrossRefPubMedGoogle Scholar
  62. 62.
    Shikhman, A. R., and Cunningham, M. W., 1994, Immunological mimicry between Nacetyl-beta-mglucosamine and cytokeratin peptides. Evidence for a microbially driven anti-keratin antibody response, J. Immunol. 152:4375–4387.PubMedGoogle Scholar
  63. 63.
    Shikhman, A. R., Greenspan, N. S., and Cunningham, M. W., 1994, Cytokeratin peptide SFGSGFGGGYmimics N-acetyl-beta-D-glucosamine in reaction with antibodies and lectins, and induces in vivo anticarbohydrate antibody response, J. Immunol. 153:5593–5606.PubMedGoogle Scholar
  64. 64.
    Shikhman, A. R., Greenspan, N. S., and Cunningham, M. W., 1993, A subset of mouse monoclonal antibodies cross-reactive with cytoskeletal proteins and group A streptococcal M proteins recognizes N-acetyl-beta-D-glucosamine, J. Immunol. 151:3902–3913.PubMedGoogle Scholar
  65. 65.
    Thurin-Blaszczyk, M., Murali, R., Westerink, M. A. J., Steplewski, Z., Co, M.-S., and Kieber-Emmons, T., 1996, Molecular recognition of the Lewis Y antigen by monoclonal antibodies, Protein Eng. 9:101–113.CrossRefGoogle Scholar
  66. 66.
    Doe, B., Steimer, K. S., and Walker, C. M., 1994, Induction of HIV-1 envelope (gp120)-specific cytotoisic T lymphocyte responses in mice by recombinant CHO cellderived gp120 is enhanced by enzymatic removal of N-linked glycans, Eur. J. Immunol. 24:2369–2376.PubMedGoogle Scholar
  67. 67.
    Haurum, J. S., Arsequell, G., Lellouch, A. C., Wong, S. Y., Dwek, R. A., McMichael, A. J., and Elliott, T., 1994, Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes, J. Exp. Med. 180:739–744.CrossRefPubMedGoogle Scholar
  68. 68.
    Haurum, J. S., Tan., L., Arsequell, G., Frodsham, P., Lellouch, A. C., Moss, P. A., Dwek, R. A., McMichael, A. J., and Elliott, T., 1995, Peptide anchor residue glycosylation: Effect on class I major histocompatibility complex binding and cytotoxic T lymphocyte recognition, Eur.J. Immunol. 25:3270–3276.PubMedGoogle Scholar
  69. 69.
    Jensen, T., Galli, S. L., Mouritsen, S., Frische, K., Peters, S., Meldal, M., and Werdelin, O., 1996, T cell recognition of Tn-glycosylated peptide antigens, Eur. J. Immunol. 26:1342–1349.PubMedGoogle Scholar
  70. 70.
    Jensen, T., Hansen, P., Galli, S. L., Mouritsen, S., Frische, K., Meinjohanns, E., Meldal, M., and Werdelin, O., 1997, Carbohydrate and peptide specificity of MHC class 11-restricted T cell hybridomas raised against an O-glycosylated self peptide, J. Immunol. 158:3769–3778.PubMedGoogle Scholar
  71. 71.
    Michaelsson, E., Broddefalk, J., Engstrom, A., Kihlberg, J., and Holmdahl, R., 1996, Antigen processing and presentation of a naturally glycosylated protein elicits major histocom-patibility complex class 11-restricted, carbohydrate-specific T cells, Eur.J. Immunol. 26:1906–1910.PubMedGoogle Scholar
  72. 72.
    Rosenthal, K. L., and Gallichan, W. S., 1997, Challenges for vaccination against sexually-transmitted diseases: Induction and long-term maintenance of mucosal immune responses in the female genital tract, Semin. Immunol. 9:303–314.CrossRefPubMedGoogle Scholar
  73. 73.
    Re, M. C., Furlini, G., Vignoli, M., Ricchi, E., Ramazzotti, E., Bianchi, S., Guerra, B., Costigliola, P., and La, P. M., 1992, Vertical transmission of human immunodeficiency virus type 1. Prognostic value of IgA antibody to HIV-1 polypeptides during pregnancy, Diagn. Microbiol.Infect.Dis. 15:553–556.PubMedGoogle Scholar
  74. 74.
    Hocini, H., Belec, L., Iscaki, S., Garin, B., Pillot, J., Becquart, P., and Bomsel, M., 1997, High-level ability of secretory IgA to block HIV type 1 transcytosis: Contrasting secretory IgA and IgG responses to glycoprotein 160, AlDS Res. Hum. Retrovir. 13:1179–1185.Google Scholar
  75. 75.
    Bukawa, H., Sekigawa, R, Hamajima, R, Fukushima, J., Yamada, Y., Kiyono, H., and Okuda, K., 1995, Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate, Nature Med. 1: 681–685.PubMedGoogle Scholar
  76. 76.
    Holmgren, J., Czerkinsky, C., Lycke, N., and Svennerholm, A. M., 1994, Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant, Am. J. Trop. Med. Hyg. 50:42–54.PubMedGoogle Scholar
  77. 77.
    Staats, H. F., Montgomery, S. P., and Palker, T. J., 1997, Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses, AIDS Res. Hum. Retrovir. 13:945–952.PubMedGoogle Scholar
  78. 78.
    Wang, B., Dang, K., Agadjanyan, M. G., Srikantan, V., Li, F., Ugen, K. E., Boyer, J., Merva, M., Williams, W. V., and Weiner, D. B., 1997, Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site, Vaccine 15:821–825.PubMedGoogle Scholar
  79. 79.
    Okada, E., Sasaki, S., Ishii, N., Aoki, I., Yasuda, T., Nishioka, K., Fukushima, J., Miyazaki, J., Wahren, B., and Okuda, R, 1997, Intranasal immunization of a DNA vaccine with IL-12-and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens, J. Immunol. 159:3638–3647.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Thomas Kieber-Emmons
    • 1
  1. 1.Department of Pathology and Laboratory MedicineUniversity of PennsylvaniaPhiladelphia

Personalised recommendations